Literature DB >> 16111669

Adiponectin serum concentrations in men with coronary artery disease: the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study.

Stefan Pilz1, Winfried Maerz, Gisela Weihrauch, Karine Sargsyan, Gunter Almer, Markus Nauck, Bernhard O Boehm, Bernhard R Winkelmann, Harald Mangge.   

Abstract

BACKGROUND: Adiponectin, the most abundant adipocytokine of adipose tissue cells, has recently been found to be decreased in coronary artery disease (CAD). Data concerning adiponectin in different stages of CAD are rare, and it was not investigated if adiponectin levels are influenced by the severity of angina pectoris.
METHODS: Thus, we measured adiponectin serum levels by means of ELISA in 1626 male probands, including 273 control subjects, 367 subjects with silent CAD, 608 patients with stable, and 378 patients with unstable angina.
RESULTS: As compared to controls (8.56; 5.85 to 12.85 microg/ml) and subjects with silent CAD (8.60; 5.99 to 12.64 microg/ml), adiponectin was significantly decreased in patients with stable (7.22; 5.06 to 10.41 microg/ml; p < 0.001 for both) and unstable angina (6.72; 4.08 to 10.08 microg/ml; p < 0.001 for both). By a logistic regression analysis, low adiponectin levels were identified as a significant independent predictor for stable and unstable angina (p < 0.001 for both). No significant differences of adiponectin were observed, neither between the stable and unstable angina group, nor between any classes of angina according to the Canadian Cardiovascular Society (CCS) Angina Score for stable angina.
CONCLUSIONS: These results suggest, that decreased adiponectin levels are indicative for symptomatic CAD, but are not further influenced by the progression of this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16111669     DOI: 10.1016/j.cccn.2005.07.011

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  High-molecular-weight and total adiponectin levels and incident symptomatic peripheral artery disease in women: a prospective investigation.

Authors:  Deborah Y Ho; Nancy R Cook; Kathryn A Britton; Eunjung Kim; Mark A Creager; Paul M Ridker; Aruna D Pradhan
Journal:  Circulation       Date:  2011-10-24       Impact factor: 29.690

2.  Adipokines, insulin resistance, and coronary artery calcification.

Authors:  Atif Qasim; Nehal N Mehta; Mahlet G Tadesse; Megan L Wolfe; Thomas Rhodes; Cynthia Girman; Muredach P Reilly
Journal:  J Am Coll Cardiol       Date:  2008-07-15       Impact factor: 24.094

3.  Reduced plasma adiponectin levels relative to oxidized low density lipoprotein and nitric oxide in coronary artery disease patients.

Authors:  Gholam Basati; Morteza Pourfarzam; Ahmad Movahedian; Saed Ziaaldin Samsamshariat; Nizal Sarrafzadegan
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  Adiponectin improves coronary no-reflow injury by protecting the endothelium in rats with type 2 diabetes mellitus.

Authors:  Xue Han; Ye Wu; Xin Liu; Lu Ma; Tingting Lv; Qi Sun; Wenli Xu; Suli Zhang; Ke Wang; Wen Wang; Xinliang Ma; Huirong Liu
Journal:  Biosci Rep       Date:  2017-07-27       Impact factor: 3.840

Review 5.  The usefulness of circulating adipokine levels for the assessment of obesity-related health problems.

Authors:  Hidekuni Inadera
Journal:  Int J Med Sci       Date:  2008-08-29       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.